MacroGenics (MGNX) News
NASDAQ: MGNXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
1.96-0.02 (-1.01%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
MGNX news summary
We found 7 recent headlines mentioning MacroGenics (MGNX): 0 in the past week and 6 in the past 30 days, most often from Nasdaq, GlobeNewswire. For price context, MGNX is down 1.01% at $1.96. The most recent story, "MacroGenics (MGNX) Reports Q3 Loss, Lags Revenue Estimates", was published by Nasdaq on Nov 12, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest MacroGenics headlines
- MacroGenics (MGNX) Reports Q3 Loss, Lags Revenue EstimatesMacroGenics (MGNX) delivered earnings and revenue surprises of -240.00% and -69.89%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?NasdaqMGNX, MDT
- MacroGenics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate ProgressROCKVILLE, Md., Nov. 12, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the…GlobeNewswire
- MacroGenics, Inc. Appoints Michael Vasconcelles and Emil Kuriakose to Board of DirectorsMacroGenics, Inc. announced that its Board of Directors approved an increase in the size of the Board from ten to eleven members, effective October 30, 2026. Upon the recommendation of the Nominating…Nasdaq
- Weekly Buzz: ABBV, PFE Win FDA Nod; ARTV Slashes Jobs; DAVI, SGRY Strike Deals(RTTNews) - The biotech sector stayed active this week, with a mix of regulatory approvals, strategic partnerships, M&A activity, and clinical trial developments.NasdaqAARD, ABBV, ARTV, AZN
- ResMed (RMD) Beats Q1 Earnings and Revenue EstimatesResMed (RMD) delivered earnings and revenue surprises of +8.99% and +1.66%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?NasdaqRMD, MGNX
- MacroGenics Announces Positive Interim Phase 2 LINNET Results for Lorigerlimab in Advanced Clear Cell Gynecologic CancerROCKVILLE, MD, Oct. 26, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the…GlobeNewswire
- MacroGenics Announces Positive Interim Phase 1 Results for MGC026 and Highlights Plans to Initiate Front-Line Combination Study in SCCHNROCKVILLE, MD, Oct. 23, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the…GlobeNewswire